胸腺肽α_1局部治疗恶性胸腔积液临床观察

Clinical study for malignant pleural effusion with thymosin α_1

目的观察胸腺肽α1(基泰)联合顺铂局部治疗恶性胸腔积液的疗效。方法 37例恶性胸腔积液患者随机分为治疗组19例,采用胸腺肽α1+顺铂灌注化疗;对照组18例,采用顺铂灌注化疗。每周1次,灌注三次后评定疗效、毒副作用、KPS评分变化。结果治疗组胸水控制有效率为68.4%。对照组为38.8%,治疗组胸水控制有效率高于对照组(P<0.05);治疗后治疗组评分改善率为78.9%;对照组为44.4%(P<0.05);两组不良反应类似,均以Ⅰ-Ⅱ度胃肠反应和骨髓抑制为主,治疗组反应发生率低于对照组,但无统计学意义(Ρ>0.05)。结论胸腺肽α1用于胸腔局部治疗时能够减毒增效,改善临床症状,提高生活质量。

Objective To observe the curative effect of thymosin α1 combined with cisplatin in treatment of malignant pleural effusion（MPE） through transpleural perfusion.Methods37 MPE patients were randomly divided into two groups：trial group（19 cases）and control group（18 cases）.Cases in trial group were treated with both thymosin α1 and cisplatin,while controls with cisplatin alone by transpleural perfusion weekly.Curative effect,toxic and side-effect,KPS score were evaluated 3 weeks after treatment.Results The regression rate of MPE were 68.4% and 38.8%（P〈0.05） and the improvement rate of KPS score were 78.9% and 44.4%（P〈0.05） in trial and control group,respectively.The toxic and side-effect were similar in both groups,which the incidence of stage 1 to 2 of the enteron toxicity and myelosuppression were more common.The incidence of toxic and side-effect was lower in trial group than control group,but there were no significant differences（P〉0.05）.ConclusionThymosin α1 could increase the curative effect,decrease the the toxic and side-effect and improve the quality of life for MPE through transpleural perfusion.